Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study

Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among immunocompromised patients with underlying malignancies and prior transplants. FDA approved Isavuconazole as a primary therapy for Invasive Aspergillosis (IA) and Mucormycosis. This study aims to compare the real-wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Batista, Marjorie Vieira, Ussetti, Maria Piedad, Jiang, Ying, Neofytos, Dionysios, Cortez, Anita Cassoli, Feriani, Diego, Schmidt-Filho, Jayr, França-Silva, Ivan Leonardo Avelino, Raad, Issam, Hachem, Ray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958690/
https://www.ncbi.nlm.nih.gov/pubmed/36836281
http://dx.doi.org/10.3390/jof9020166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958690/
https://www.ncbi.nlm.nih.gov/pubmed/36836281
http://dx.doi.org/10.3390/jof9020166

Ejemplares similares